Last reviewed · How we verify
NCT06852274
Clostridium Butyricum CBM588® vs. Rifaximin for Symptomatic Uncomplicated Diverticular Disease (SUDD): A Real-World Retrospective Study
NA trial testing Clostridium butyricum CBM588® (Butirrisan®) in Diverticular Diseases in 70 participants. Completed in 31 October 2024.
30 April 2024
Quick facts
| Lead sponsor | Dr. Amjad Khan |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 70 |
| Start date | 1 March 2023 |
| Primary completion | 30 April 2024 |
| Estimated completion | 31 October 2024 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Clostridium butyricum CBM588® (Butirrisan®)
- Rifaximin 400 mg Oral Tablet
Conditions studied
- Diverticular Diseases — all drugs for Diverticular Diseases →
- Gastro-Intestinal Disorder — all drugs for Gastro-Intestinal Disorder →
Sponsor
Dr. Amjad Khan
Who can join
18 and older, any sex, with Diverticular Diseases or Gastro-Intestinal Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This retrospective, real-world, single-center clinical study aimed to evaluate the effectiveness of probiotic Clostridium butyricum CBM588® (Butirrisan®) versus Rifaximin in the management of Symptomatic Uncomplicated Diverticular Disease (SUDD). Patients with diverticulosis and a history of mild-to-moderate diverticulitis were included, and their clinical outcomes were assessed using existing patient records. The study compared two treatment groups: Experimental Group: Clostridium butyricum CBM588® (Butirrisan®) + fiber supplementation. Control Group: Rifaximin + fiber supplementation. The primary endpoint was the reduction in SUDD symptoms, evaluated using patient-reported outcomes. Secondary outcomes included assessment of safety, risk of surgery, and changes in abdominal pain frequency and severity.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Management of symptomatic uncomplicated diverticular disease (SUDD) of the colon with Clostridium butyricum CBM588 versus rifaximin: a retrospective cross-sectional study.
Urgesi R, Pagnini C, De Angelis F, Khan A, et al · · 2025 · PMID 41108431 · DOI 10.1007/s00384-025-05005-6
Verify or expand the search:
- PubMed search for NCT06852274
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diverticular Diseases
Currently open trials in the same condition.
- NCT05829343 — RObotic Versus LAparoscopic Colectomy for DIverticulitis. · recruiting
- NCT06797739 — Effect of Nutritional Counseling and Mediterranean Diet on Patients With Diverticular Disease · NA · active not recruiting
Other Dr. Amjad Khan trials
Trials by the same sponsor.
- NCT05871255 — Natural Topical Treatment for Vulvar and Vaginal Atrophy · completed
- NCT05871242 — Study to Investigate the Treatment Benefit of Probiotic Lactobacillus Crispatus M247 in Women Undergoing Homologous Leve · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06852274 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dr. Amjad Khan
- Last refreshed: 18 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06852274.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing